MorphoSys Announces Clinical Milestone in Oncology Program
22 December 2014 - 5:46PM
MorphoSys AG (FSE:MOR; Prime Standard Segment, TecDAX, OTC: MPSYY)
announced today that it has received a milestone payment from
Novartis in connection with the initiation of a phase 1 clinical
trial of a HuCAL antibody in the field of oncology. This becomes
the tenth therapeutic antibody made using MorphoSys's technologies
that Novartis is evaluating in clinical trials. The associated
milestone payment is booked in 2014.
"In 2014 our pipeline, and our collaborators' pipelines of
therapeutic antibodies have matured significantly and now include
more programs in clinical trials and in a more advanced state than
ever before. Today's news represents the fourth clinical milestone
with our partners during the course of the year," commented Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
MorphoSys's collaboration with Novartis has resulted in ten
clinical programs to date, five of which are in phase 1
development, with another four programs in phase 2 and one in phase
3. In total, MorphoSys's partnered and proprietary clinical
pipeline currently comprises 22 unique antibody molecules which are
being evaluated in more than 60 clinical trials.
About MorphoSys: MorphoSys developed HuCAL, the most successful
antibody library technology in the pharmaceutical industry. By
successfully applying this and other patented technologies,
MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human
healthcare. Together with its pharmaceutical partners, MorphoSys
has built a therapeutic pipeline of more than 90 human antibody
drug candidates for the treatment of cancer, rheumatoid arthritis,
and Alzheimer's disease, to name just a few. With its ongoing
commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit
http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,
arYla® and Ylanthia® and 100 billion high potentials® are
registered trademarks of MorphoSys AG. Slonomics® is a registered
trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys
AG.
This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as
of the date of this release and involve risks and uncertainties.
Should actual conditions differ from the Company's assumptions,
actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is
concerned.
For more information, please contact:
MorphoSys AG Dr. Claudia Gutjahr-Löser Head of Corporate
Communications & IR
Mario Brkulj Associate Director Corporate Communications &
IR
Alexandra Goller Specialist Corporate Communications &
IR
Jessica Rush Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404 investors@morphosys.com
Media Release (PDF)
http://hugin.info/130295/R/1882093/663980.pdf
HUG#1882093
Morgan Stanley Morgan Stanley Capital Protected Notes Based ON S&P 500 (AMEX:MOR)
Historical Stock Chart
From Apr 2024 to May 2024
Morgan Stanley Morgan Stanley Capital Protected Notes Based ON S&P 500 (AMEX:MOR)
Historical Stock Chart
From May 2023 to May 2024